Liraglutide

Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) developed as an acylated analogue of the endogenous incretin hormone GLP-1. Originally approved for the management of type 2 diabetes mellitus (under the trade name Victoza) and subsequently for chronic weight management (Saxenda), liraglutide exerts its primary pharmacological effects by binding to and activating the GLP-1 receptor (Glucagon-like peptide-1 receptor (GLP-1R)), a G protein-coupled receptor expressed in pancreatic beta cells, the central nervous system, and multiple peripheral tissues. Receptor activation stimulates cAMP production and downstream signaling through cAMP-dependent protein kinase catalytic subunits, leading to glucose-dependent insulin secretion, suppression of glucagon release, delayed gastric emptying, and reduction of food intake. Its fatty acid side chain confers a plasma half-life of approximately 13 hours, enabling once-daily subcutaneous administration. The molecule exists in a pH-dependent oligomeric equilibrium in solution, a biophysical property with implications for formulation stability and drug delivery.

Beyond its established metabolic indications, liraglutide has emerged as a pleiotropic therapeutic agent with demonstrated or investigated activity across neuropsychiatric, oncological, neurodegenerative, and organ-protective domains. Its structural similarity to other clinically deployed GLP-1RAs, including semaglutide, and to the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide, has made it a key comparator in mechanistic studies probing the shared and divergent biological activities of this drug class. Active investigation of novel delivery systems, particularly oral formulations, reflects ongoing efforts to broaden accessibility and patient adherence beyond the injectable route.